Key Points Summary of 金域医学 Conference Call Company Overview - **Company**: 金域医学 (Kingmed Diagnostics) - **Industry**: Medical Diagnostics and AI in Healthcare Core Insights and Arguments - **AI Medical Model Launch**: 金域医学 launched China's first medical testing industry AI model "小医医", serving over 370,000 doctors with nearly 200,000 active users, indicating its leadership in AI healthcare [2][3] - **Digital Transformation**: The company is actively exploring digital transformation to enhance operational efficiency and develop new business growth points, collaborating with hospitals like 中山三院 and local health authorities [2][5] - **Market Potential**: The AI healthcare market is projected to reach 5-6 trillion RMB, with revenue from AI and data-related businesses expected to exceed 100 million RMB from May to December 2025, and a forecasted revenue range of 50 million to 200 million RMB for 2026 [2][3] - **Strategic Partnerships**: Collaborations with hospitals and pharmaceutical companies are crucial, with hospitals being the main revenue source and pharmaceutical partnerships providing higher profit margins [11][12] Financial Performance and Projections - **Data as Core Asset**: In 2025, data revenue accounted for nearly 30% of total income, with a significantly higher profit margin compared to other AI-related businesses [3][17] - **Profitability Goals**: The company aims for a net profit margin of 6% to 8% in the short term, with strategies to improve efficiency and reduce costs amid hospital fee control pressures [3][20] - **Revenue Growth**: Expected positive revenue growth in 2026, with a focus on expanding into the pharmaceutical market to complement hospital business [20][11] Industry Dynamics - **Government Strategy**: The Chinese government aims for a 70% AI coverage in medical institutions by 2027, indicating strong demand for AI solutions in healthcare [7] - **Market Spending Trends**: Information technology spending in hospitals is expected to rise from 3% to 5% of revenue in the AI era, with the overall healthcare market potentially reaching 5-6 trillion RMB [9][10] - **Cost Control Trends**: Ongoing pressure on hospital testing fees is expected, with strategies in place to enhance efficiency and reduce costs through centralized procurement and digital transformation [19][24] Future Directions - **Product Development**: A detailed product line plan for 2026 includes quarterly releases of new products tailored to various hospital needs, focusing on standardized products and specialized AI applications [13] - **Collaboration Expansion**: Plans to increase partnerships with over 30 pharmaceutical companies, emphasizing the importance of high-quality data and rapid delivery [18][11] - **Focus on Smart Healthcare**: The company aims to become a preferred partner in smart healthcare, leveraging accumulated data and AI technology to support hospitals and related industries [6][28] Additional Important Insights - **Revenue from AI Products**: Hospital demand for AI products varies, with project costs typically ranging from 500,000 to 1 million RMB, and diverse pricing models including one-time fees and revenue-sharing [10] - **Impact of AI Models**: The "遇见医眼" and "小医医" models are foundational for AI applications, with plans to enhance their capabilities for both doctors and patients [15][16] - **Market Trends**: The trend towards outsourcing in large hospitals is expected to grow, driven by cost awareness and improved policy environments, which may lead to rapid revenue increases [24]

Core Insights - The 2025 World Internet of Things Conference Industrial Internet Forum was successfully held in Beijing, focusing on the theme of "Industrial Internet Industry Entering ASEAN and Empowering High-Quality Development in the Medical and Pharmaceutical Sector" [1][3] - The forum aimed to explore opportunities for the industrial internet to expand internationally and discussed how to leverage industrial internet technology to enhance the digital, networked, and intelligent upgrades of grassroots healthcare [1] Group 1: Key Speakers and Their Contributions - Keynote speeches were delivered by prominent figures including Li Zhengmao, President of the Global Cloud Network Broadband Industry Association, and Nie Yuchun, President of the China Information Industry Chamber of Commerce, emphasizing the importance of industrial internet in reshaping global industrial competitiveness and driving high-quality economic development [2][5][7] - The forum featured reports from experts such as Tan Jianrong from Zhejiang University, Gu Ning from Nanjing University, and Zhang Hongke from Beijing Jiaotong University, covering topics like the integration of artificial intelligence in medical engineering and advancements in cardiovascular medicine [12][14][15][18] Group 2: Industry Development and Cooperation - The RCEP Industrial Cooperation Committee highlighted the growing trade relationship between China and ASEAN, with bilateral trade continuing to increase, and emphasized the need for deeper policy and industry alignment to seize new opportunities [9] - The forum underscored the necessity for international collaboration and the establishment of industrial internet cooperation mechanisms to enhance regional cooperation and inject new momentum into industrial innovation [9][10] Group 3: Practical Applications and Case Studies - The China Information Industry Chamber of Commerce released a collection of outstanding industrial internet case studies from 39 companies across various sectors, demonstrating significant economic benefits and positive social impacts [21] - The forum included discussions on innovative applications of industrial internet technology in high-end manufacturing, transportation, and healthcare, showcasing the potential for improved efficiency and effectiveness in these fields [15][18][22]

Core Viewpoint - The development of medical AI is essential and cannot be achieved by a single institution alone; collaboration among various organizations is necessary for innovation and practical application [1]. Group 1: Medical AI Development - Medical AI is identified as a highly promising area for application due to the vast amount of data, diverse scenarios, and urgent public needs in the healthcare sector [1]. - The integration of AI can significantly enhance the capabilities of primary care physicians, allowing them to quickly improve their skills without extensive training [1]. - Despite advancements in AI, it cannot replace the human aspects of medicine, such as understanding patients' emotional and psychological needs [1]. Group 2: Systemic Innovation and Collaboration - The uneven distribution of medical resources and weak primary care capabilities in China necessitate innovative solutions through new information technologies [1]. - The development of medical AI requires a systemic approach that combines technological innovation, institutional reform, and ecological collaboration [1]. - The establishment of an "AI + Healthcare" innovation circle in the Guangdong-Hong Kong-Macao Greater Bay Area is proposed to optimize data management and support AI applications in healthcare [1]. Group 3: Data Management and Ecosystem - The launch of the credible data space by KingMed Medical aims to facilitate safe data circulation within a compliant framework, enhancing the value of AI in clinical settings [2]. - The goal is to create a smart healthcare ecosystem that ensures innovative solutions reach grassroots levels and benefit the public [2].

Core Insights - The establishment of the "Roche Excellence Demonstration Center" by Rudong People's Hospital in collaboration with Roche Diagnostics aims to enhance the hospital's comprehensive medical service capabilities and promote the construction of smart laboratories [1][3]. Group 1: Hospital Development - Rudong People's Hospital plays a pivotal role as a regional medical center, driving improvements in healthcare services across the county through various initiatives such as paired assistance and standardized management [3]. - The hospital is collaborating with tertiary hospitals in Shanghai and Nanjing to enhance the quality of medical resources available to local residents [3]. Group 2: Diagnostic Advancements - The hospital's laboratory department conducts nearly 500 testing projects, with an annual testing volume exceeding 10 million, serving as the clinical testing quality control center for the county [3]. - The introduction of the CCM laboratory automation solution has led to full-process automation and intelligent management, significantly improving operational efficiency and reducing sample turnaround time by over 50% [3]. - The automated testing platform connected through CCM allows for a wider range of biochemical and immunological tests from a single blood sample, thereby reducing the burden of blood collection and enhancing patient experience [3].

Group 1 - The core point of the news is that Selys Medical has seen a stock price increase of 5.89%, reaching 26.24 CNY per share, with a total market capitalization of 5.515 billion CNY [1] - Selys Medical, established on February 23, 2004, and listed on October 31, 2016, is primarily engaged in medical testing, marketing services, and the development, production, and sales of in vitro diagnostic products [1] - The revenue composition of Selys Medical includes 39.91% from IVD business, 38.01% from SPD business, and 22.08% from pure sales [1] Group 2 - According to data, one fund under Caitong Securities Asset Management holds a significant position in Selys Medical, with 200,000 shares, representing 5.72% of the fund's net value, ranking as the tenth largest holding [2] - Caitong Asset Management Healthcare Mixed A Fund (018484) has achieved a year-to-date return of 26.65% and a one-year return of 24.44%, ranking 3236 out of 8150 and 3250 out of 8043 respectively [2] - The fund was established on August 3, 2023, with a current scale of 64.3006 million CNY, and has generated an estimated floating profit of approximately 292,000 CNY today [2]

Core Insights - The deployment of the DeepGEM model by Guangzhou Kingmed Diagnostics Group aims to enhance cancer diagnosis through accurate and timely gene mutation predictions [1][2] - The collaboration involves Tencent and Guangzhou Medical University First Affiliated Hospital, focusing on developing a multimodal model for pathology and genetics [1][2] Group 1: DeepGEM Model Development - DeepGEM provides accurate predictions of gene mutations related to lung cancer, achieving a prediction accuracy of 78% to 99% within one minute [1] - The model addresses the challenges of conventional gene testing methods, which are often complex, time-consuming, and costly, particularly in resource-limited areas [1] Group 2: Clinical Application and Future Plans - Following successful validation, the three parties will promote the clinical application of DeepGEM for lung cancer gene mutation prediction [2] - There are plans to further develop a multimodal model that integrates various omics data, including pathology, proteomics, and metabolomics, for AI-assisted diagnosis across multiple cancer types [2] Group 3: Vision and Collaboration - The initiative aims to serve as a model for translating clinical research into practical applications, benefiting the public [2] - Kingmed Diagnostics expresses a desire to collaborate with more partners to create intelligent and accessible clinical diagnostic solutions [2]

Group 1 - The core point of the news is that Sely Medical's stock price increased by 5.55% to 26.42 CNY per share, with a trading volume of 246 million CNY and a turnover rate of 4.62%, resulting in a total market capitalization of 5.553 billion CNY [1] - Sely Medical Technology Group Co., Ltd. is based in Wuhan, Hubei Province, and was established on February 23, 2004, with its listing date on October 31, 2016. The company's main business involves centralized marketing and service for medical testing, as well as the agency and independent research, production, and sales of in vitro diagnostic products [1] - The revenue composition of Sely Medical includes IVD business at 39.91%, SPD business at 38.01%, and pure sales at 22.08% [1] Group 2 - From the perspective of the top ten circulating shareholders, the Caitong Fund has one fund among the top shareholders of Sely Medical. The Caitong Advantage Industry Rotation Mixed A Fund (011201) entered the top ten circulating shareholders in the second quarter, holding 643,400 shares, which accounts for 0.34% of the circulating shares. The estimated floating profit today is approximately 894,300 CNY [2] - The Caitong Advantage Industry Rotation Mixed A Fund (011201) was established on February 9, 2021, with a latest scale of 536 million CNY. Year-to-date returns are 17.35%, ranking 4543 out of 8161 in its category; the one-year return is 8.66%, ranking 5742 out of 8015; and since inception, it has a loss of 28.59% [2]

Core Insights - The collaboration between Guangzhou Jinyu Medical, Tencent, and Guangzhou Medical University aims to develop an AI model called DeepGEM for predicting gene mutations in tumor patients using conventional pathological images [1][5][6] - The DeepGEM model has shown promising results in accurately predicting lung cancer gene mutations, achieving a precision rate between 78% and 99% [2][3] - The partnership is expected to enhance the clinical application of DeepGEM and expand its capabilities to other cancer types, integrating various omics data for a comprehensive diagnostic approach [6] Group 1: Development of DeepGEM Model - The DeepGEM model was developed by a team from Guangzhou Medical University and Tencent, utilizing AI to predict lung cancer gene mutations from pathological images [2][3] - The model can process different types of biopsy samples and generate spatial distribution maps of gene mutations, enhancing the understanding of mutation patterns within tissues [3][4] - The model's performance has been validated with a large dataset from Jinyu Medical, covering 4,260 lung cancer patient samples across various medical institutions [4] Group 2: Clinical Implications and Future Directions - The collaboration aims to provide timely and cost-effective gene diagnostics, especially for patients in resource-limited areas, by combining AI screening with targeted gene confirmation [3][6] - The successful deployment of DeepGEM at Jinyu Medical marks a significant milestone in the exploration of multi-modal AI models for pathology and genetics [6] - Jinyu Medical's extensive data repository and commitment to integrating AI in medical testing are expected to lead to advancements in diagnosing not only tumors but also rare and complex diseases [5][6]

Core Insights - The collaboration between Kingmed Medical, Tencent, and Guangzhou Medical University First Affiliated Hospital aims to develop the AI model DeepGEM for predicting gene mutations in cancer patients using routine pathological images [1][5][6] - DeepGEM has demonstrated a high accuracy rate of 78% to 99% in predicting common lung cancer driver gene mutations, significantly improving the efficiency and accessibility of genetic diagnostics [2][4] Group 1: Development and Technology - DeepGEM is developed by a collaboration between Guangzhou Medical University First Affiliated Hospital, Guangzhou Respiratory Health Research Institute, and Tencent, marking a significant advancement from traditional pathology to genetic insights [1][3] - The model utilizes innovative techniques such as Multiple Instance Learning (MIL) and an end-to-end architecture that enhances prediction accuracy without the need for manual tumor region annotation [3][4] Group 2: Clinical Application and Validation - Kingmed Medical is providing a large-scale dataset for validating DeepGEM, with over 15,000 NGS tests conducted annually and a sample size of 4,260 lung cancer patients across various medical institutions [4][5] - The model has reached clinical auxiliary diagnostic levels for identifying mutations in genes like EGFR, KRAS, and ALK, showcasing its robustness and compatibility for clinical use [4][6] Group 3: Future Prospects and Expansion - The partnership aims to expand the application of DeepGEM beyond lung cancer to other cancer types, integrating various omics data for a comprehensive diagnostic approach [5][6] - The collaboration is seen as a milestone in the exploration of AI-driven pathology-genetics models, with aspirations to enhance the efficiency of clinical research and diagnostics in both cancer and rare diseases [6]

Group 1 - The core point of the news is that Selys Medical experienced a stock price increase of 5.04%, reaching 25.65 CNY per share, with a trading volume of 267 million CNY and a turnover rate of 5.12%, resulting in a total market capitalization of 5.39 billion CNY [1] - Selys Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, and was established on February 23, 2004, with its listing date on October 31, 2016. The company's main business involves centralized marketing and service for medical testing, as well as the agency and independent research, production, and sales of in vitro diagnostic products [1] - The revenue composition of Selys Medical includes IVD business at 39.91%, SPD business at 38.01%, and pure sales at 22.08% [1] Group 2 - From the perspective of the top ten circulating shareholders of Selys Medical, data shows that a fund under Caitong Fund ranks among the top ten shareholders. The Caitong Advantage Industry Rotation Mixed A Fund (011201) entered the top ten shareholders in the second quarter, holding 643,400 shares, which accounts for 0.34% of the circulating shares [2] - The Caitong Advantage Industry Rotation Mixed A Fund (011201) was established on February 9, 2021, with a latest scale of 536 million CNY. Year-to-date returns are 19.74%, ranking 4636 out of 8167 in its category; the one-year return is 22.47%, ranking 4803 out of 8010; and since inception, it has a loss of 27.14% [2]